PmpI antibody reduces the inhibitory effect of Vp1 on Chlamydia trachomatis infectivity.

Can J Microbiol

Dermatology and Venereology Department, Tianjin Medical University General Hospital, 154 Anshan Road, Heping District, Tianjin 300052, People's Republic of China.

Published: June 2018

AI Article Synopsis

Article Abstract

Chlamydia trachomatis is the most common cause of bacterial sexually transmitted infections. The effect of antibiotic treatment is not satisfactory, and there is currently no vaccine to prevent C. trachomatis infection. Our results showed that Chlamydia virus CPG1 capsid protein Vp1 treatment significantly inhibited C. trachomatis growth in cell culture, and the inclusion numbers of different C. trachomatis serotypes were decreased. In addition, we conducted a preliminary investigation of the possible mechanisms behind the Vp1 inhibition effects and the C. trachomatis molecules targeted by Vp1. Using far-western blot and GST pull-down assay, we found that purified Vp1 can bind to the C. trachomatis outer membrane protein PmpI. PmpI polyclonal antibody treatment markedly reduced the inhibitory effect of Vp1 on C. trachomatis infectivity. On the basis of these experimental results, we infer that PmpI participates in the inhibitory effect of Vp1 and may be a potential receptor of Vp1 in the outer membrane of C. trachomatis. Our research provides clues regarding the molecular mechanisms underlying the interactions between chlamydia virus and chlamydia.

Download full-text PDF

Source
http://dx.doi.org/10.1139/cjm-2018-0056DOI Listing

Publication Analysis

Top Keywords

inhibitory vp1
12
trachomatis
9
vp1
8
chlamydia trachomatis
8
trachomatis infectivity
8
chlamydia virus
8
outer membrane
8
chlamydia
5
pmpi
4
pmpi antibody
4

Similar Publications

Background: BK polyomavirus (BKV) DNAaemia occurs in 10% of recipients of kidney transplants, contributing to premature allograft failure. Evidence suggests disease is donor derived. Hypothetically, recipient infection with a different BKV serotype increases risk due to poorer immunological control.

View Article and Find Full Text PDF

Characterization of the immunodominant regions of Senecavirus A-VP1 structural protein via ELISA epitope mapping.

Vet Microbiol

November 2024

Veterinary Diagnostic Laboratory, Veterinary Diagnostic and Production Animal Medicine, Iowa State University, Ames, IA, USA. Electronic address:

Article Synopsis
  • - Senecavirus A (SVA) is a virus affecting swine, linked to diseases that can cause significant mortality in piglets, and is made up of four proteins, with VP1 being the most immunogenic, yet little is known about its specific immune regions.
  • - The study aimed to map immunodominant regions of SVA's polyprotein using ELISA techniques, revealing that various VP1-derived peptides were recognized by antibodies, with one peptide showing particularly high binding.
  • - Results indicated specific peptides inhibited antibody binding, with some located on the outer surface of the virus capsid, suggesting potential for future research on their roles in immune response and vaccine development.
View Article and Find Full Text PDF

In the primary visual cortex area V1 activation of inhibitory interneurons, which provide negative feedback for excitatory pyramidal neurons, can improve visual response reliability and orientation selectivity. Moreover, optogenetic activation of one class of interneurons, parvalbumin (PV) positive cells, reduces the receptive field (RF) width. These data suggest that in V1 the negative feedback improves visual information processing.

View Article and Find Full Text PDF

Pro-inflammatory autoantigen-specific CD4 T helper (auto-Th) cells are central orchestrators of autoimmune diseases (AIDs). We aimed to characterize these cells in human AIDs with defined autoantigens by combining human leukocyte antigen (HLA)-tetramer-based and activation-based multidimensional ex vivo analyses. In aquaporin4-antibody-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD) patients, auto-Th cells expressed CD154, but proliferative capacity and pro-inflammatory cytokines were strongly reduced.

View Article and Find Full Text PDF

Tanomastat exerts multi-targeted inhibitory effects on viral capsid dissociation and RNA replication in human enteroviruses.

EBioMedicine

September 2024

Laboratory of Molecular RNA Virology and Antiviral Strategies, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; NUSMed Biosafety Level 3 Core Facility, Yong Loo Lin School of Medicine, National University of Singapore, 14 Medical Drive, 117599, Singapore; Infectious Disease Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, 117597, Singapore; Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A∗STAR), 61 Biopolis Drive, Proteos #06-05, 138673, Singapore. Electronic address:

Article Synopsis
  • Human enterovirus A71 (EV-A71) is a significant neurotropic virus with limited approved treatments, prompting research into repurposing existing drugs like Tanomastat.* -
  • In laboratory studies, Tanomastat was found to inhibit EV-A71 replication in a dose-dependent manner by targeting early stages of the viral lifecycle, particularly interfering with the viral capsid.* -
  • Tanomastat showed promising results in vivo, providing 85% protection and symptom relief in EV-A71-infected neonatal mice, suggesting it could be a valuable candidate for broader anti-enterovirus therapy.*
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!